AACR Data Highlights InNexus Preclinical Antibody Candidate

InNexus Biotechnology Inc. (Toronto Stock Exchange: IXS.V, a drug development company commercializing the next generation of monoclonal antibodies based on its technology, Dynamic Cross Linking (DXL(TM)), announced that the company will be presenting new data on its lead preclinical candidate DXL625 (CD20) for the prospective treatment of Non Hodgkin’s Lymphoma (NHL) at the annual meeting of the American Association for Cancer Research (AACR), April 18-22, in Denver.

More: continued here

Filed under: Clinical Trials on April 10th, 2009